Researchers Push Next Frontier in Hepatitis C Elimination: Ultra-Short DAA Treatment Courses in Sight

Hepatitis C was once a textbook example of why chronic viral infections can be so difficult to eliminate at scale. Treatment was long, toxic and hard to deliver through routine health systems. Over the past decade, however, simple oral direct-acting antivirals (DAAs) have reshaped the landscape—turning cure into the expected outcome for most people and making national elimination strategies technically feasible. Now, researchers are pushing the next frontier: making treatment even shorter, with the goal of accelerating population-wide cure and reducing the logistical burden of care.

The arc of hepatitis C therapy shows just how dramatic the change has been. The first wave of DAAs—protease inhibitors used alongside interferon and ribavirin—still required roughly 24 to 48 weeks of therapy, with substantial side effects and complicated monitoring. Early proof-of-concept studies later showed that all-oral DAA regimens could cure infection without interferon, but treatment courses were still measured in months. As combinations improved, clinical trials began testing whether 12 weeks could be enough, and those efforts largely succeeded: cure rates—measured as sustained virologic response (SVR)—were consistently high across common patient groups.

The introduction of pan-genotypic fixed-dose combinations further simplified care, allowing many patients to be treated without extensive genotype-specific tailoring. Yet even today, the standard course in most clinical guidelines remains about 12 weeks for the majority of patients, with shorter durations reserved for selected, lower-risk groups. In some settings, an 8-week course can be used for people without cirrhosis under defined criteria, reflecting the cautious balance regulators and clinicians strike between simplicity and certainty of cure.

The elimination challenge is not whether DAAs work, but whether health systems can deliver them to everyone who needs them. Global estimates put the number of people living with chronic hepatitis C at around 71 million. Many are undiagnosed; many face barriers to repeated clinic visits; many live in countries where laboratory capacity and specialist care are limited. In that context, shortening treatment is not merely a matter of convenience—it becomes a lever for scale.

Studies exploring 6-week, 4-week and even 3-week strategies aim to reduce what public health planners often call “patient drop-off”: the longer the regimen, the more opportunities for missed doses, missed appointments and discontinuation. Researchers have also reported that adherence tends to fall as pill burden and duration increase, creating a straightforward rationale for shorter courses. Cost dynamics add another layer. Total treatment expense includes not only medication but also diagnostics, clinician time and follow-up visits. A regimen that safely compresses care from 12 weeks to 4 weeks could, in principle, allow health budgets to treat far more people with the same overall resources—an especially compelling prospect for high-burden countries running mass treatment programs.

But biology sets limits, and the evidence suggests those limits differ between patient subgroups. Multiple short-course trials have shown that 6-week combinations can work well in carefully selected patients, particularly those without cirrhosis. When researchers attempted to cut to 4 weeks, outcomes worsened in several studies, indicating that ultra-short therapy is not yet robust across diverse real-world populations. In at least one trial program, response patterns suggested that viral subtype mattered: people with genotype 1B appeared more likely to achieve SVR on very short regimens than those with genotype 1A when treated for fewer than six weeks. In a small study in China, investigators reported SVR in all participants treated for three weeks using triple-drug combinations in a narrowly defined group—patients without cirrhosis and with genotype 1B infection—highlighting what may be possible, while also underscoring how targeted these successes remain.

One worry that has shadowed the short-course idea is drug resistance: if a regimen is too short and fails, could it select resistant virus and make retreatment harder? Retreatment data from early short-duration trials have been reassuring. Across multiple programs using different DAA combinations, most people who did not achieve SVR with an abbreviated course were subsequently cured with standard-length therapy, often using the same backbone drugs. That experience suggests resistance, while still monitored, may not be the primary obstacle to testing shorter strategies.

The larger challenge is operational: can short-course therapy be made simple enough that clinicians do not have to “pick and choose” based on cirrhosis status, baseline viral load or viral subtype? Critics argue that elimination demands regimens that work broadly with minimal pre-treatment workup, because complexity itself becomes a barrier. Proponents of shortened therapy counter that even stepwise simplification—first identifying the groups in whom 6 weeks works reliably, then expanding—could speed progress while researchers pursue a universal ultra-short option.

For now, the evidence points to a pragmatic middle ground: 12 weeks remains the dependable default, 8 weeks is appropriate for some, and 6-week strategies may be a near-term target for selected patients without cirrhosis as data mature. The ambition of 3–4 week “treatment sprints” is scientifically credible, but not yet ready to replace standard care across all populations.

Why it matters

Hepatitis C is curable, but elimination depends on reaching millions of people who are currently outside consistent medical care. Shorter regimens could reduce drop-off, lower delivery costs, and make mass treatment campaigns more feasible—especially in high-burden countries. The remaining question is whether ultra-short therapy can be made reliably effective without complex patient selection, a prerequisite for truly scalable elimination.